Asahi Kasei (3407) Q3 2026 earnings summary

Executive summary

• Operating income for Apr.–Dec. 2025 rose 6.2% year-over-year to ¥173.9 billion, with net income up 22.7% to ¥120.6 billion, driven by strong Healthcare and Homes segments, despite a decline in Material.

• Net sales for Q1–Q3 2025 were ¥2,261,263 million, up 0.1% year-over-year.

• Comprehensive income increased to ¥209,222 million from ¥152,841 million year-over-year.

• FY 2025 operating income is forecast to reach a record ¥225.0 billion (+6.2% YoY), with net income projected at ¥145.0 billion (+7.4% YoY), both revised upward from previous forecasts.

• Shareholder returns include a full-year dividend forecast of ¥40 per share (up ¥2 YoY) and a share repurchase program of up to ¥40 billion initiated in November 2025.

Financial highlights

• Gross profit for Q1–Q3 2025 was ¥745,820 million, up from ¥716,582 million in the prior year.

• EBITDA for Apr.–Dec. 2025 was ¥319.8 billion (+6.7% YoY), with an EBITDA margin of 14.1%.

• Non-operating income/expenses improved, but extraordinary losses increased due to business discontinuations and structural reforms.

• D/E ratio declined to 0.51 as of Dec. 2025, with interest-bearing debt reduced by ¥59.5 billion.

• Net worth ratio improved to 48.1% from 46.3% at the previous fiscal year-end.

Outlook and guidance

• FY 2025 net sales are forecast at ¥3,065.0 billion (+0.9% YoY), with operating income at ¥225.0 billion (+6.2% YoY) and net income at ¥145.0 billion (+7.4% YoY).

• Operating income is expected to reach a new record for the second consecutive year, led by Pharmaceuticals and Electronics, and supported by a weaker yen.

• Dividend payout ratio and progressive dividend policy maintained, with ongoing share repurchase.

• Net income per share forecasted at ¥106.83 for the full year.

• Performance forecasts are subject to change due to unforeseen factors.